Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG).

Finbar Slevin¹, Brad Warkentin², Jeremy Hansen³, Ann M Henry¹, Louise J Murray¹, Donna H Murrell⁴, Wee Loon Ong⁵, David Pasquier⁶

¹Leeds Institute of Medical Research, University of Leeds, UK and Leeds Teaching Hospitals NHS Trust, Leeds, UK.

²Department of Oncology, Division of Medical Physics, University of Alberta; Department of Medical Physics, Cross Cancer Institute, Cancer Care Alberta; Edmonton, Alberta, Canada.

³Varian Medical Systems, Housten, TX, USA.

⁴Department of Oncology, Western University, London, Ontario, Canada; Verspeeten Family Cancer Centre, London Health Sciences Centre, London, Ontario, Canada.

⁵Alfred Radiation Oncology, Bayside Health, School of Translational Medicine, Monash University, Melbourne, Victoria Australia; Department of Radiation Oncology, Andrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

⁶Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France; Lille University, CRIStAL UMR CNRS 9189, Lille, France.

PubMed PMC DOI PDF

Abstract

There is considerable uncertainty regarding the optimum approaches to target volume and organ at risk (OAR) delineation and tolerances to reirradiation for locally recurrent prostate cancer. To address these uncertainties, we undertook a literature review of treatment planning approaches of stereotactic body radiotherapy (SBRT) or brachytherapy reirradiation in published and ongoing prospective st…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.